Safe donated blood is critical to improving certain patient outcomes. Transfusion-transmitted infections (TTI) persist despite interventions used to reduce risk. Bacterial contamination presents the most significant infectious risk, followed by the emergence of new pathogens such as dengue, chikungunya and zika.
While current screening tests have lowered the risks from transfusion transmitted infections, these tests are reactive, requiring identification of specific pathogens for which to develop and implement tests.
This activity will outline how blood safety is changing and methodologies to identify and mitigate the risks associated with blood product transfusions.
- Recognize the incidence of bacterial contamination of platelets for transfusion
- Understand the clinical presentation and consequences of infections from contaminated blood products
- Describe approaches for mitigation of bacterial contamination of blood products, especially platelets, for transfusion
- Identify the signs and symptoms of a transfusion-transmitted bacterial infection and review follow-up actions
Level of Instruction
Author / Speaker
Kent Carter, BS PharmD
Medical Outreach Director
Kent Carter, BS PharmD earned his BS and PharmD at Auburn University and completed residencies at West Virginia University/Charleston Area Medical Center and Hermann Hospital/UT in Houston specializing in Trauma and Critical Care. He served the Senior Clinical Pharmacist at The Methodist Hospital in Houston where he also directed the anticoagulation service. Based on his critical care, surgical and coagulation experience, Kent developed an interest and became extremely knowledgeable in all potential adverse events associated with blood products and the ensuing concerns regarding patient safety. Kent joined the biotechnology industry and further developed his expertise in immunology, cardiopulmonary, hemolytic anemias and clotting factors/hemostasis, and bloodstream and medical device infections. Kent joined Cerus Corporation in 2014 as a key team member at the forefront of professional education regarding new technologies to enhance blood safety directed to medical professionals associated with blood product transfusions.
Cerus Corporation is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
Contact Hour: 1.0
Expires on: Apr 13, 2023 at 11:59 pm CT
This program is approved by the California Board of Registered Nursing, Provider Number CEP15148 for 1.0 contact hours
Contact Hour: 1.0
Expires at: Jun 1, 2023 at 12:00 am CT
Technical Requirements and Assistance
Questions or Comments
Please contact firstname.lastname@example.org.